In addition to gefitinib, several EGFR-TKIs including afatinib and osimertinib have since been developed and approved for first-line treatment of advanced NSCLC harboring EGFR-activating mutations [17]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.